Penn-Pfizer Partnership to Accelerate Real-World Evidence in Cancer
Penn and Pfizer are partnering to conduct a real-world evaluation of FDA-approved targeted therapies in cancer. We are developing approaches to accelerate the use of real-world evidence in cancer care.
Pfizer, Penn Center for Pharmacoepidemiology Research and Training (CPeRT), and the Department of Biostatistics, Epidemiology and Informatics (DBEI)
This project is currently in progress.